The  	The  	 DT	O
β-Blocker  	β-Blocker  	 JJ	B-NP
to  	to  	 TO	O
Lower  	Lower  	 NNP	O
Cardiovascular  	Cardiovascular  	 NNP	B-NP
Dialysis  	Dialysis  	 NNP	I-NP
Events  	Events  	 NNP	I-NP
( 	( 	 -LRB-	O
BLOCADE 	BLOCADE 	 NNP	B-NP
)  	)  	 -RRB-	O
Feasibility  	Feasibility  	 NNP	B-NP
Study 	Study 	 NNP	I-NP
:  	:  	 :	O
A  	A  	 DT	O
Randomized  	Randomized  	 NNP	O
Controlled  	Controlled  	 NNP	B-NP
Trial  	Trial  	 NNP	I-NP
β-Blocking  	β-Blocking  	 JJ	I-NP
agents  	agents  	 NNS	I-NP
reduce  	reduce  	 VB	O
cardiovascular  	cardiovascular  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
heart  	heart  	 NN	B-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
their  	their  	 PRP$	O
potential  	potential  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
in  	in  	 IN	O
dialysis  	dialysis  	 NN	B-NP
patients  	patients  	 NNS	I-NP
is  	is  	 VBZ	O
unclear 	unclear 	 JJ	O
.  	.  	 .	O
We  	We  	 PRP	O
aimed  	aimed  	 VBD	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
feasibility  	feasibility  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
randomized  	randomized  	 JJ	B-NP
controlled  	controlled  	 JJ	I-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Pilot  	Pilot  	 NNP	B-NP
RCT 	RCT 	 NNP	I-NP
.  	.  	 .	O
Patients  	Patients  	 NNS	O
who  	who  	 WP	O
received  	received  	 VBD	B-NP
dialysis  	dialysis  	 NN	I-NP
for  	for  	 IN	O
3  	3  	 CD	O
or  	or  	 CC	O
more  	more  	 JJR	O
months  	months  	 NNS	O
and  	and  	 CC	O
were  	were  	 VBD	O
50  	50  	 CD	O
years  	years  	 NNS	O
or  	or  	 CC	O
older  	older  	 JJR	O
( 	( 	 -LRB-	O
or ≥18  	or ≥18  	 CD	O
years  	years  	 NNS	O
with  	with  	 IN	O
diabetes  	diabetes  	 NN	O
or  	or  	 CC	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease 	disease 	 NN	I-NP
)  	)  	 -RRB-	O
were  	were  	 VBD	O
recruited  	recruited  	 VBN	O
from  	from  	 IN	O
11  	11  	 CD	O
sites  	sites  	 NNS	O
in  	in  	 IN	O
Australia  	Australia  	 NNP	B-NP
and  	and  	 CC	O
New  	New  	 NNP	B-NP
Zealand 	Zealand 	 NNP	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
aimed  	aimed  	 VBD	O
to  	to  	 TO	O
recruit  	recruit  	 VB	O
150  	150  	 CD	O
participants 	participants 	 NNS	B-NP
.  	.  	 .	O
After  	After  	 IN	O
a  	a  	 DT	O
6-week  	6-week  	 JJ	O
run-in  	run-in  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
β-blocker  	β-blocker  	 JJ	B-NP
carvedilol 	carvedilol 	 NN	I-NP
,  	,  	 ,	O
we  	we  	 PRP	O
randomly  	randomly  	 RB	O
assigned  	assigned  	 VBN	B-NP
participants  	participants  	 NNS	I-NP
to  	to  	 TO	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
carvedilol  	carvedilol  	 NN	B-NP
or  	or  	 CC	O
placebo  	placebo  	 NN	O
for  	for  	 IN	O
12  	12  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
prespecified  	prespecified  	 JJ	B-NP
primary  	primary  	 JJ	I-NP
outcome  	outcome  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
who  	who  	 WP	O
tolerated  	tolerated  	 VBP	O
carvedilol 	carvedilol 	 VBN	O
,  	,  	 ,	O
6.25mg 	6.25mg 	 NNP	O
,  	,  	 ,	O
twice  	twice  	 RB	O
daily  	daily  	 JJ	O
during  	during  	 IN	O
the  	the  	 DT	O
run-in  	run-in  	 JJ	O
period 	period 	 NN	O
.  	.  	 .	O
After  	After  	 IN	O
randomization 	randomization 	 NN	B-NP
,  	,  	 ,	O
we  	we  	 PRP	O
report  	report  	 VBP	O
participant  	participant  	 JJ	B-NP
withdrawal  	withdrawal  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
intradialytic  	intradialytic  	 JJ	B-NP
hypotension  	hypotension  	 NNS	I-NP
( 	( 	 -LRB-	O
IDH 	IDH 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Of  	Of  	 IN	O
1,443  	1,443  	 CD	O
patients  	patients  	 NNS	O
screened 	screened 	 VBD	O
,  	,  	 ,	O
354  	354  	 CD	O
were  	were  	 VBD	O
eligible 	eligible 	 JJ	O
,  	,  	 ,	O
91  	91  	 CD	O
consented 	consented 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
72  	72  	 CD	O
entered  	entered  	 VBD	O
the  	the  	 DT	O
run-in  	run-in  	 JJ	O
stage.  	stage.  	 CD	O
49  	49  	 CD	O
of  	of  	 IN	O
72  	72  	 CD	O
run-in  	run-in  	 JJ	O
participants  	participants  	 NNS	B-NP
( 	( 	 -LRB-	O
68 	68 	 CD	O
% 	% 	 NN	O
;  	;  	 :	O
95 	95 	 CD	O
%  	%  	 NN	O
CI 	CI 	 NNP	O
,  	,  	 ,	O
57 	57 	 CD	O
% 	% 	 NN	O
-79 	-79 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
achieved  	achieved  	 VBD	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
outcome.  	outcome.  	 CD	I-NP
5  	5  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
23  	23  	 CD	O
withdrawals  	withdrawals  	 NNS	O
from  	from  	 IN	O
run-in  	run-in  	 NNP	O
were  	were  	 VBD	O
attributable  	attributable  	 JJ	O
to  	to  	 TO	O
bradycardia  	bradycardia  	 VB	O
or  	or  	 CC	O
hypotension 	hypotension 	 NN	B-NP
.  	.  	 .	O
After  	After  	 IN	O
randomization 	randomization 	 NN	B-NP
,  	,  	 ,	O
10  	10  	 CD	O
of  	of  	 IN	O
26  	26  	 CD	O
allocated  	allocated  	 VBN	O
to  	to  	 TO	O
carvedilol  	carvedilol  	 VB	O
and  	and  	 CC	O
4  	4  	 CD	O
of  	of  	 IN	O
23  	23  	 CD	O
allocated  	allocated  	 VBN	O
to  	to  	 TO	O
placebo  	placebo  	 CD	O
withdrew.  	withdrew.  	 CD	O
4  	4  	 CD	O
participants  	participants  	 NNS	B-NP
randomly  	randomly  	 RB	O
assigned  	assigned  	 VBN	O
to  	to  	 TO	O
carvedilol  	carvedilol  	 VB	O
withdrew  	withdrew  	 VBN	O
because  	because  	 IN	O
of  	of  	 IN	O
bradycardia  	bradycardia  	 NN	B-NP
or  	or  	 CC	O
hypotension 	hypotension 	 NN	B-NP
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
4  	4  	 CD	O
IDH  	IDH  	 NN	B-NP
events  	events  	 NNS	I-NP
per  	per  	 IN	O
100  	100  	 CD	O
hemodialysis  	hemodialysis  	 CD	B-NP
sessions 	sessions 	 NNS	I-NP
;  	;  	 :	O
in  	in  	 IN	O
participants  	participants  	 NNS	B-NP
allocated  	allocated  	 VBN	O
to  	to  	 TO	O
carvedilol  	carvedilol  	 FW	B-NP
versus  	versus  	 FW	O
placebo 	placebo 	 FW	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
7  	7  	 CD	O
versus  	versus  	 CD	O
2  	2  	 CD	O
IDH  	IDH  	 NN	B-NP
events  	events  	 NNS	I-NP
per  	per  	 IN	O
100  	100  	 CD	O
hemodialysis  	hemodialysis  	 CD	B-NP
sessions  	sessions  	 NNS	I-NP
( 	( 	 -LRB-	O
P=0.1 	P=0.1 	 NNP	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
2  	2  	 CD	O
weeks  	weeks  	 NNS	O
immediately  	immediately  	 RB	O
following  	following  	 VBG	O
a  	a  	 DT	O
dose  	dose  	 NN	O
increase  	increase  	 NN	O
and  	and  	 CC	O
4  	4  	 CD	O
versus  	versus  	 CD	O
3  	3  	 CD	O
IDH  	IDH  	 NN	B-NP
events  	events  	 NNS	I-NP
per  	per  	 IN	O
100  	100  	 CD	O
hemodialysis  	hemodialysis  	 CD	B-NP
sessions  	sessions  	 NNS	I-NP
after  	after  	 IN	O
no  	no  	 DT	O
dose  	dose  	 NN	O
increase  	increase  	 NN	O
( 	( 	 -LRB-	O
P=0.7 	P=0.7 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Unable  	Unable  	 JJ	O
to  	to  	 TO	O
recruit  	recruit  	 VB	O
planned  	planned  	 JJ	O
sample  	sample  	 NN	O
size 	size 	 NN	O
.  	.  	 .	O
Recruiting  	Recruiting  	 VBG	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
dialysis  	dialysis  	 NN	I-NP
to  	to  	 TO	O
an  	an  	 DT	O
RCT  	RCT  	 NNP	B-NP
of  	of  	 IN	I-NP
β-blocker  	β-blocker  	 FW	I-NP
versus  	versus  	 FW	O
placebo  	placebo  	 FW	O
will  	will  	 MD	O
prove  	prove  	 VB	O
challenging 	challenging 	 VBG	O
.  	.  	 .	O
Possible  	Possible  	 JJ	B-NP
solutions  	solutions  	 NNS	I-NP
include  	include  	 VBP	O
international  	international  	 JJ	O
collaboration  	collaboration  	 NN	B-NP
and  	and  	 CC	O
exploring  	exploring  	 VBG	B-NP
novel  	novel  	 NN	I-NP
trial  	trial  	 NN	I-NP
designs  	designs  	 VBZ	O
such  	such  	 JJ	O
as  	as  	 IN	O
a  	a  	 DT	O
registry-based  	registry-based  	 JJ	B-NP
RCT 	RCT 	 NNP	I-NP
.  	.  	 .	O
